109 related articles for article (PubMed ID: 20201993)
1. Insulin analogues and cancer risk: cause for concern or cause célèbre?
Pollak M; Russell-Jones D
Int J Clin Pract; 2010 Apr; 64(5):628-36. PubMed ID: 20201993
[TBL] [Abstract][Full Text] [Related]
2. [Diabetes, insulin, insulin analogues, and cancer].
Müssig K; Staiger H; Kantartzis K; Fritsche A; Kanz L; Häring HU
Dtsch Med Wochenschr; 2010 May; 135(18):924-9. PubMed ID: 20425680
[TBL] [Abstract][Full Text] [Related]
3. Insulin, insulin analogues and cancer: no cause for panic.
Thomson GA
Int J Clin Pract; 2010 Apr; 64(5):525-7. PubMed ID: 20456201
[No Abstract] [Full Text] [Related]
4. Cancer risk in diabetic patients treated with insulin glargine?
Prescrire Int; 2010 Aug; 19(108):162-3. PubMed ID: 20939447
[TBL] [Abstract][Full Text] [Related]
5. [Safety of insulin analogues: what to evaluate, how to do it, and how to interpret the results].
Hernández Mijares A; Solá Izquierdo E; García Malpartida K; Verge D
Endocrinol Nutr; 2010 Oct; 57(8):376-80. PubMed ID: 20621572
[TBL] [Abstract][Full Text] [Related]
6. Diabetes mellitus and the risk of cancer.
Pandey A; Forte V; Abdallah M; Alickaj A; Mahmud S; Asad S; McFarlane SI
Minerva Endocrinol; 2011 Sep; 36(3):187-209. PubMed ID: 22019750
[TBL] [Abstract][Full Text] [Related]
7. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs.
McFarland MS; Cripps R
Pharmacotherapy; 2010 Nov; 30(11):1159-78. PubMed ID: 20973689
[TBL] [Abstract][Full Text] [Related]
8. [Insulin and cancer: myth or reality?].
Tran C; Gariani K; Philippe J
Rev Med Suisse; 2010 Jun; 6(252):1188-90, 1192. PubMed ID: 20614753
[TBL] [Abstract][Full Text] [Related]
9. Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes.
Le Roith D
Diabetes Metab Res Rev; 2007 Nov; 23(8):593-9. PubMed ID: 17922476
[TBL] [Abstract][Full Text] [Related]
10. Insulin--carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research.
Call R; Grimsley M; Cadwallader L; Cialone L; Hill M; Hreish V; King ST; Riche DM
Postgrad Med; 2010 May; 122(3):158-65. PubMed ID: 20463425
[TBL] [Abstract][Full Text] [Related]
11. Type 2 diabetes mellitus and risk of malignancy: is there a strategy to identify a subphenotype of patients with increased susceptibility to endogenous and exogenous hyperinsulinism?
Müssig K; Staiger H; Kantartzis K; Fritsche A; Kanz L; Häring HU
Diabet Med; 2011 Mar; 28(3):276-86. PubMed ID: 21309835
[TBL] [Abstract][Full Text] [Related]
12. Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy.
Edwards KL; Riche DM; Stroup JS; Goldman-Levine JD; Padiyara RS; Cross LB; Kane MP
Pharmacotherapy; 2010 Sep; 30(9):955-65. PubMed ID: 20795850
[TBL] [Abstract][Full Text] [Related]
13. Biphasic insulin aspart in the treatment of type 2 diabetes mellitus.
Cucinotta D; Russo GT
Expert Opin Pharmacother; 2009 Dec; 10(17):2905-11. PubMed ID: 19929709
[TBL] [Abstract][Full Text] [Related]
14. Putting insulin glargine and malignancies into perspective.
Ehninger G; Schmidt AH
Oncologist; 2009 Dec; 14(12):1169-74. PubMed ID: 20007644
[No Abstract] [Full Text] [Related]
15. Insulin glargine (Lantus) and cancer risk.
Med Lett Drugs Ther; 2009 Aug; 51(1319):67-8. PubMed ID: 19696708
[No Abstract] [Full Text] [Related]
16. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
17. Where now for insulin glargine--a time for pragmatic medicine?
Thomson GA; Craig R
Int J Clin Pract; 2009 Oct; 63(10):1413-5. PubMed ID: 19689485
[No Abstract] [Full Text] [Related]
18. Insulin therapy in elderly patients with type 2 diabetes: the role of insulin glargine.
Janka HU
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():35-41. PubMed ID: 18577155
[TBL] [Abstract][Full Text] [Related]
19. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
Bode BW
Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
[TBL] [Abstract][Full Text] [Related]
20. Diabetes mellitus type 2 - an independent risk factor for cancer?
Grote VA; Becker S; Kaaks R
Exp Clin Endocrinol Diabetes; 2010 Jan; 118(1):4-8. PubMed ID: 20127570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
